Gold bars to be exempt from tariffs, White House clarifies
BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), a $2.29 billion pharmaceutical company with robust revenue growth of 16.7% in the last twelve months, has revealed new data from its RISE-PD Phase 3 study, demonstrating significant improvements in sleep quality for Parkinson’s disease (PD) patients treated with CREXONT. According to InvestingPro analysis, the company shows strong financial health with an EBITDA of $584.6 million. The study showed a mean difference in Parkinson’s Disease Sleep Scale-2 (PDSS-2) total scores of -2.35 (p
CREXONT, a novel formulation of CD/LD, combines immediate-release granules and extended-release pellets, aiming to provide rapid onset and sustained release of levodopa. The analysis indicated significant enhancements across all PDSS-2 subdomains, including reduced disturbed sleep and improved nighttime motor symptoms.
The findings will be presented at the American Academy of Neurology (AAN) 2025 Annual Meeting on April 9. Dr. Robert Hauser, a study author, emphasized the importance of addressing sleep disturbances in PD management, noting CREXONT’s potential to improve patient care and well-being. With analysts maintaining a bullish outlook and InvestingPro data suggesting the stock is currently undervalued, Amneal’s innovative treatments could drive future growth. Get access to detailed analysis and 8 additional ProTips about AMRX with an InvestingPro subscription.
A separate study analysis highlighted more patients waking up in an ’On’ state and fewer reporting an ’Off’ state upon awakening when treated with CREXONT versus IR CD/LD. Joe Renda from Amneal Pharmaceuticals commented on the positive impact of CREXONT and the company’s commitment to enhancing PD patient outcomes.
Amneal has initiated a Phase 4 clinical trial, ELEVATE-PD, to further assess the real-world efficacy and safety of CREXONT in PD patients. The most common side effects reported were nausea and anxiety, and patients are advised against abrupt discontinuation or rapid dose reduction.
Parkinson’s disease, a progressive neurological disorder, affects approximately 1 million people in the U.S. CREXONT’s formulation differs from RYTARY, another extended-release carbidopa and levodopa capsule approved by the U.S. FDA in 2015.
This report is based on a press release statement from Amneal Pharmaceuticals, Inc. The company maintains a healthy free cash flow yield of 10%, positioning it well for continued investment in innovative treatments. For comprehensive insights into Amneal’s financial health and growth prospects, access the full Pro Research Report, available exclusively on InvestingPro.
In other recent news, Amneal Pharmaceuticals reported its Q4 2024 earnings, revealing a slight miss on earnings per share (EPS) expectations, with EPS at $0.12 compared to the anticipated $0.15. However, the company exceeded revenue forecasts, reaching $731 million against the expected $703.74 million. Amneal demonstrated robust growth in 2024, with total revenue climbing to $2.8 billion, marking a 17% increase year-over-year. The company has launched a new Parkinson’s drug, Krexant, which has shown promising sales targets and is expected to significantly contribute to future revenue. Additionally, Amneal has announced the FDA’s acceptance of their Biologics Licensing Application for two biosimilars of denosumab, indicating a strategic move to expand its presence in the U.S. biosimilars market. The company has projected a revenue guidance range of $3.0 to $3.1 billion for 2025, implying a growth rate of 7-11%. Furthermore, Amneal plans to continue its debt reduction strategy, aiming for a net leverage below 3x in the coming years. S&P and Moody’s have upgraded Amneal’s credit rating, reflecting improved financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.